As of 2024-12-14, the Relative Valuation of NextCell Pharma AB (NXTCL.ST) is (18.80) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 2.02 SEK, the upside of NextCell Pharma AB based on Relative Valuation is -1030.8%.
The range of the Relative Valuation is (18.63) - (18.24) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.7x - 31.8x | 31.8x |
| Forward P/E multiples | 32.5x - 35.0x | 33.8x |
| Fair Price | (18.63) - (18.24) | (18.80) |
| Upside | -1022.5% - -1003.2% | -1030.8% |
| Date | P/E |
| 2024-11-29 | -3.05 |
| 2024-11-28 | -3.08 |
| 2024-11-27 | -3.05 |
| 2024-11-26 | -2.94 |
| 2024-11-25 | -2.93 |
| 2024-11-22 | -3.01 |
| 2024-11-21 | -3.07 |
| 2024-11-20 | -3.01 |
| 2024-11-19 | -3.00 |
| 2024-11-18 | -3.05 |
| 2024-11-15 | -3.10 |
| 2024-11-14 | -3.14 |
| 2024-11-13 | -3.12 |
| 2024-11-12 | -3.14 |
| 2024-11-11 | -3.10 |
| 2024-11-08 | -3.03 |
| 2024-11-07 | -3.14 |
| 2024-11-06 | -3.05 |
| 2024-11-05 | -3.00 |
| 2024-11-04 | -3.00 |
| 2024-11-01 | -3.05 |
| 2024-10-31 | -3.01 |
| 2024-10-30 | -3.12 |
| 2024-10-29 | -3.10 |
| 2024-10-28 | -3.05 |
| 2024-10-25 | -3.21 |
| 2024-10-24 | -3.34 |
| 2024-10-23 | -3.38 |
| 2024-10-22 | -3.43 |
| 2024-10-21 | -3.38 |
| 2024-10-18 | -3.59 |
| 2024-10-17 | -3.29 |
| 2024-10-16 | -3.36 |
| 2024-10-15 | -3.31 |
| 2024-10-14 | -3.55 |
| 2024-10-11 | -3.73 |
| 2024-10-10 | -3.62 |
| 2024-10-09 | -3.66 |
| 2024-10-08 | -3.66 |
| 2024-10-07 | -3.80 |
| 2024-10-04 | -3.59 |
| 2024-10-03 | -3.27 |
| 2024-10-02 | -3.12 |
| 2024-10-01 | -3.08 |
| 2024-09-30 | -3.05 |
| 2024-09-27 | -2.91 |
| 2024-09-26 | -2.75 |
| 2024-09-25 | -2.91 |
| 2024-09-24 | -3.01 |
| 2024-09-23 | -3.07 |